5842 Federal Register / Vol. 74, No. 20 / Monday, February 2, 2009 / Notices 

August 3, 2001, renewed at appropriate 

intervals, and will expire on August 3, 

2009. 

Purpose: This Advisory Board is 

charged with (a) Providing advice to the 

Secretary, HHS, on the development of 

guidelines under Executive Order 

13179; (b) providing advice to the 

Secretary, HHS, on the scientific 

validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advise the Secretary on 

whether there is a class of employees at 

any Department of Energy facility who 

were exposed to radiation but for whom 

it is not feasible to estimate their 

radiation dose, and on whether there is 

reasonable likelihood that such 

radiation doses may have endangered 

the health of members of this class. 

Matters to be Discussed: The agenda 

for the Advisory Board meeting 

includes: NIOSH Program Status 

Update; NIOSH and Department of 

Energy (DOE) Security Plans; 

Department of Labor (DOL) Update; 

Special Exposure Cohort (SEC) Petitions 

for: Los Alamos National Laboratory, 

Westinghouse Atomic Power 

Development, Tyson Valley Powder 

Farm, General Steel Industries, Hood 

Building (Massachusetts Institute of 

Technology), and Blockson Chemical; 

SC&A New Technical Support Contract; 

Special Exposure Cohort (SEC) Petition 

Status Updates; Science Update; Work 

Group reports; Subcommittee on Dose 

Reconstruction Reviews Report; 

Subcommittee on Procedures Reviews 

and Board Future Plans and Meetings. 

The agenda is subject to change as 

priorities dictate. 

In the event an individual cannot 

attend, written comments may be 

submitted according to the policy 

provided below. Any written comments 

received will be provided at the meeting 

and should be submitted to the contact 

person below well in advance of the 

meeting. 

Policy on Redaction of Board Meeting 

Transcripts (Public Comment), (1) If a 

person making a comment gives his or 

her name, no attempt will be made to 

redact that name. (2) NIOSH will take 

reasonable steps to ensure that 

individuals making public comment are 

aware of the fact that their comments 

(including their name, if provided) will 

appear in a transcript of the meeting 

posted on a public Web site. Such 

reasonable steps include: (a) A 

statement read at the start of each public 

comment period stating that transcripts 

will be posted and names of speakers 

will not be redacted; (b) A printed copy 

of the statement mentioned in (a) above 

will be displayed on the table where 

individuals sign up to make public 

comment; (c) A statement such as 

outlined in (a) above will also appear 

with the agenda for a Board Meeting 

when it is posted on the NIOSH Web 

site; (d) A statement such as in (a) above 

will appear in the Federal Register 

Notice that announces Board and 

Subcommittee meetings. (3) If an 

individual in making a statement 

reveals personal information (e.g., 

medical information) about themselves 

that information will not usually be 

redacted. The NIOSH FOIA coordinator 

will, however, review such revelations 

in accordance with the Freedom of 

Information Act and the Federal 

Advisory Committee Act and if deemed 

appropriate, will redact such 

information. (4) All disclosures of 

information concerning third parties 

will be redacted. (5) If it comes to the 

attention of the DFO that an individual 

wishes to share information with the 

Board but objects to doing so in a public 

forum, the DFO will work with that 

individual, in accordance with the 

Federal Advisory Committee Act, to 

find a way that the Board can hear such 

comments. 

CONTACT PERSON FOR MORE INFORMATION: 

Theodore Katz, M.P.A., Executive 

Secretary, NIOSH, CDC, 1600 Clifton 

Road, MS E–20, Atlanta, GA 30333, 

Telephone (513) 533–6800, Toll Free 1 

(800) CDC–INFO, E-mail ocas@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: January 22, 2009. 

Lorenzo J. Falgiano, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E9–2165 Filed 1–30–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Immunization 

Practices (ACIP) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Times and Dates: 

8 a.m.–5 p.m., February 25, 2009. 

8 a.m.–5 p.m., February 26, 2009. 

Place: Centers for Disease Control and 

Prevention, Tom Harkin Global 

Communications Center, 1600 Clifton 

Road, NE., Building 19, Kent ‘‘Oz’’ 

Nelson Auditorium, Atlanta, Georgia 

30333. 

Status: Open to the public, limited 

only by the space available. 

Purpose: The committee is charged 

with advising the Director, CDC, on the 

appropriate uses of immunizing agents. 

In addition, under 42 U.S.C. 1396s, the 

committee is mandated to establish and 

periodically review and, as appropriate, 

revise the list of vaccines for 

administration to vaccine-eligible 

children through the Vaccines for 

Children (VFC) program, along with 

schedules regarding the appropriate 

periodicity, dosage, and 

contraindications applicable to the 

vaccines. 

Matters to be Discussed: The agenda 

will include discussions on Anthrax; 

Hepatitis Vaccines; Measles, Mumps 

and Rubella; Influenza Vaccine; 

Pneumococcal Vaccines; Rabies 

Vaccine; General Recommendations; 

Human Papillomavirus Vaccines; 

Herpes Zoster; Meningococcal Vaccine; 

MMRV Vaccine Safety; Pertussis; Polio 

Vaccine; Vaccine Safety; Vaccine 

Supply; Vaccination of Immigrants and 

refugees; Yellow Fever. Agenda items 

are subject to change as priorities 

dictate. 

Contact Person for More Information: 

Antonette Hill, Immunization Services 

Division, National Center for 

Immunization and Respiratory Diseases, 

CDC, 1600 Clifton Road, NE., (E–05), 

Atlanta, Georgia 30333, telephone 404/ 

639–8836, fax 404/639–8905. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: January 22, 2009. 

Lorenzo J. Falgiano, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E9–2164 Filed 1–30–09; 8:45 am] 

BILLING CODE 4160–18–P 


dwashington3 on PROD1PC60 with NOTICES